Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemiaStéphane Picard(Inserm), François‐Xavier Mahon(Hammersmith Hospital)BloodDecember 27, 200610.1182/blood-2006-07-036012Cited by 604SaveCiteExport RISWatch citationsRelated PapersMDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models|Blood|2003|538Synergistic cooperation between ABT-263 and MEK1/2 inhibitor: effect on apoptosis and proliferation of acute myeloid leukemia cells|Oncotarget|2015|21